The Sechenov University in Moscow, Russia, has completed the human clinical trials of the first COVID-19 vaccine in the world. It is a significant development in the challenge against coronavirus that has affected over 200 countries with a lack of vaccine and treatment procedures.
The chief and head researcher of the Center for Clinical Research on Medications, Elena Smolyarchuk, from the Sechenov University reported that the vaccine is effective as per the findings of their study.
Russia authorized the human clinical trials for their two vaccine formulations against coronavirus in June. The Burdenko Military Hospitals tested an intramuscular solution of the COVID-19 vaccine while the powder form was used for the intramuscular solution by the Sechenov University.
The COVID-19 vaccine was tested on small and large animals prior to human trials to confirm it’s safety, immunogenicity, effectiveness, and toxicity by the Central Research Institute. The initial stage of the COVID-19 vaccine involved 18 participants on June 18, while the second group of 20 participants was tested for the vaccine on June 23. Smolyarchuk reported,
“The research has been completed, and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20.”
Moreover, the trial participants will remain in isolation for about 28 days after discharge and will be monitored in the outpatient services.
The Director of the Institute of Translational Medicine and Biotechnology, Vadim Tarasov commented,
“Sechenov University in a pandemic situation acted not only as an educational institute but also as a scientific and technological research center that is able to participate in the creation of such an important and technological research center.”
According to the World Health Organization, around the globe, about 21 coronavirus vaccines are under the trial.